Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher, Kena C. Miller, David Lawrence, Amy Whitworth, Francisco Hernandez-Ilizaliturri, Myron S. Czuczman, Austin Miller, William Lawrence, Syed Ali Bilgrami, Raman Sood, Margaret T. Wood, Annemarie W. Block, Kelvin Lee, Asher A Chanan Khan

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalLeukemia and Lymphoma
Volume51
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cytogenetics
Phase II Clinical Trials
lenalidomide
Disease-Free Survival
Survival
Therapeutics
Population

Keywords

  • Chronic lymphocytic leukemia
  • Fludarabine-refractory
  • High-risk cytogenetics
  • Lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. / Sher, Taimur; Miller, Kena C.; Lawrence, David; Whitworth, Amy; Hernandez-Ilizaliturri, Francisco; Czuczman, Myron S.; Miller, Austin; Lawrence, William; Bilgrami, Syed Ali; Sood, Raman; Wood, Margaret T.; Block, Annemarie W.; Lee, Kelvin; Chanan Khan, Asher A.

In: Leukemia and Lymphoma, Vol. 51, No. 1, 01.2010, p. 85-88.

Research output: Contribution to journalArticle

Sher, T, Miller, KC, Lawrence, D, Whitworth, A, Hernandez-Ilizaliturri, F, Czuczman, MS, Miller, A, Lawrence, W, Bilgrami, SA, Sood, R, Wood, MT, Block, AW, Lee, K & Chanan Khan, AA 2010, 'Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics', Leukemia and Lymphoma, vol. 51, no. 1, pp. 85-88. https://doi.org/10.3109/10428190903406806
Sher, Taimur ; Miller, Kena C. ; Lawrence, David ; Whitworth, Amy ; Hernandez-Ilizaliturri, Francisco ; Czuczman, Myron S. ; Miller, Austin ; Lawrence, William ; Bilgrami, Syed Ali ; Sood, Raman ; Wood, Margaret T. ; Block, Annemarie W. ; Lee, Kelvin ; Chanan Khan, Asher A. / Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 1. pp. 85-88.
@article{7dea72a981a3474c9d6951bc46af16b4,
title = "Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics",
abstract = "Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38{\%}, with 19{\%} of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58{\%}, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.",
keywords = "Chronic lymphocytic leukemia, Fludarabine-refractory, High-risk cytogenetics, Lenalidomide",
author = "Taimur Sher and Miller, {Kena C.} and David Lawrence and Amy Whitworth and Francisco Hernandez-Ilizaliturri and Czuczman, {Myron S.} and Austin Miller and William Lawrence and Bilgrami, {Syed Ali} and Raman Sood and Wood, {Margaret T.} and Block, {Annemarie W.} and Kelvin Lee and {Chanan Khan}, {Asher A}",
year = "2010",
month = "1",
doi = "10.3109/10428190903406806",
language = "English (US)",
volume = "51",
pages = "85--88",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

AU - Sher, Taimur

AU - Miller, Kena C.

AU - Lawrence, David

AU - Whitworth, Amy

AU - Hernandez-Ilizaliturri, Francisco

AU - Czuczman, Myron S.

AU - Miller, Austin

AU - Lawrence, William

AU - Bilgrami, Syed Ali

AU - Sood, Raman

AU - Wood, Margaret T.

AU - Block, Annemarie W.

AU - Lee, Kelvin

AU - Chanan Khan, Asher A

PY - 2010/1

Y1 - 2010/1

N2 - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

AB - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

KW - Chronic lymphocytic leukemia

KW - Fludarabine-refractory

KW - High-risk cytogenetics

KW - Lenalidomide

UR - http://www.scopus.com/inward/record.url?scp=74949083498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949083498&partnerID=8YFLogxK

U2 - 10.3109/10428190903406806

DO - 10.3109/10428190903406806

M3 - Article

C2 - 20055660

AN - SCOPUS:74949083498

VL - 51

SP - 85

EP - 88

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -